Calliditas Therapeutics AB's quarterly market cap
increased
from Jun. 2023 ($425.07 Mil) to Sep. 2023 ($490.03 Mil) and
increased
from Sep. 2023 ($490.03 Mil) to Dec. 2023 ($690.87 Mil).
Calliditas Therapeutics AB's annual market cap
declined
from Dec. 2021 ($647.99 Mil) to Dec. 2022 ($456.21 Mil) but then
increased
from Dec. 2022 ($456.21 Mil) to Dec. 2023 ($690.87 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Calliditas Therapeutics AB's Enterprise Value for Today is $499.99 Mil.
Calliditas Therapeutics AB Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Calliditas Therapeutics AB's Market Cap
For the Biotechnology subindustry, Calliditas Therapeutics AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Calliditas Therapeutics AB's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Calliditas Therapeutics AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Calliditas Therapeutics AB's Market Cap falls into.
Calliditas Therapeutics AB Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Calliditas Therapeutics AB (NAS:CALT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Calliditas Therapeutics AB Market Cap Related Terms
Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.
Calliditas Therapeutics AB (Calliditas Therapeutics AB) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CALT has been successfully added to your 